PreVitaCOV

Prednisolone and vitamin B1, 6 and 12 in patients withPost-COVID-19-Syndrome (PC19S) – a randomised controlled pilot trial in primary care

01/02/2022 to 31/01/2024

Up to 80% of patients develop post-COVID-19 syndrome (PC19S) after SARS-CoV-2 infection. This can be manifested by various complaints such as fatigue, exhaustion, headaches, olfactory and gustatory disturbances, cognitive impairments and depressive moods that persist for more than 3 months. Affected individuals are predominantly cared for by their primary care physicians, but scientific evidence for therapies is lacking to date. Assuming autoimmunological and chronic inflammatory processes, drug treatment with cortisone and neurotropic B vitamins is being investigated. The present pilot study tests the feasibility of this approach in patients and patients in primary care, in a double-blind, randomized-placebo-controlled design.